Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
17.21
+0.61 (3.67%)
At close: Aug 13, 2025, 4:00 PM
17.15
-0.06 (-0.35%)
After-hours: Aug 13, 2025, 7:04 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.18B in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.14
Revenue / Employee
$451,480
Employees
36,830
Market Cap
19.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TEVA News
- 8 days ago - US FDA approves Teva's Ajovy for migraine prevention in children - Reuters
- 13 days ago - Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside - Seeking Alpha
- 14 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Teva Pharm Q2 profit beats estimates as branded drugs gain - Reuters
- 15 days ago - Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong - Benzinga
- 6 weeks ago - Teva Releases Q2 2025 Aide Memoire - GlobeNewsWire
- 7 weeks ago - Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 - GlobeNewsWire
- 7 weeks ago - Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine - GlobeNewsWire